Startup profile for Freenome: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Freenome funding, valuation and investors

AI-driven multi-cancer early detection from a routine blood draw.

Keep track of Freenome

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Strategic

$290M · January 2022

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$590M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth

Investors in latest funding

Lead: Roche

Sources: latest funding Last verified: 2026-07-25

Overview

Freenome develops blood-based multi-cancer early detection tests that combine genomics, proteomics, and machine learning. The company's path to market depends on large-scale clinical validation and regulatory approval.

Why Freenome is interesting

Freenome is a high-stakes diagnostics AI company — clinical validation and FDA clearance are the whole game, with $590M+ raised including Roche strategic investment.

Product & use cases

AI-driven multi-cancer early detection blood tests combining genomics, proteomics, and machine learning.

  • Multi-cancer screening from routine blood draw
  • Early detection before symptoms appear
  • Clinical validation for FDA approval pathway

Key facts

  • Series D (Dec 2021): $300M with Bain Capital Life Sciences (/fund/bain-capital-ventures) and a16z Life Sciences Growth Fund (/fund/andreessen-horowitz) (Freenome press)
  • Roche invested $290M (Jan 2022) as strategic partner; Roche Venture Fund not in VCT directory

Funding history (newest first)

Strategic

2022-01 $290M
  • Roche (lead)

Source: https://www.freenome.com/press/roche-investment

Series D

2021-12 $300M

Source: https://www.freenome.com/press/series-d

Investors in our directory

Funds linked from Freenome's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Bain Capital Ventures

Competitive landscape

Edge: $590M+ raised including Roche $290M strategic investment — clinical validation is the entire game.

Liquid biopsy for multi-cancer screening is one of healthtech's highest-stakes bets. Freenome's $300M Series D (2021) plus Roche's $290M strategic investment (2022) fund clinical trials — success requires both AI accuracy and regulatory approval.

  • Grail (Galleri) direct

    Multi-cancer early detection competitor.

  • Guardant Health adjacent

    Liquid biopsy leader; broader oncology focus.

  • Exact Sciences incumbent

    Cologuard colon screening; different cancer focus.

Notable stories

  • Roche invested $290M in Freenome as a strategic partner for multi-cancer screening development (Freenome press, 2022).

Industries

Healthtech Biotech & Life Sciences AI & Machine Learning

FAQs about Freenome

Practical answers founders, operators, and investors typically search for.

Freenome builds AI-powered blood tests for multi-cancer early detection, combining genomic and proteomic signals with machine learning to screen for cancer before symptoms appear.
Freenome's $300M Series D (Dec 2021) included Andreessen Horowitz (/fund/andreessen-horowitz) and Bain Capital Ventures (/fund/bain-capital-ventures). Roche also invested $290M in Jan 2022 as a strategic partner.
Freenome is at Series D based on its December 2021 $300M round, with additional strategic investment from Roche in 2022.
Liquid biopsy for multi-cancer screening is one of the highest-stakes bets in healthtech — success requires both AI model accuracy and rigorous clinical trials. Freenome sits at that intersection.
No. Freenome remains a private company.
Both pursue multi-cancer blood screening; different biomarker approaches and trial stages.
$590M+ including $300M Series D and $290M Roche strategic investment.
Not yet — clinical validation and regulatory approval are ongoing.
All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.